We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Submission

USE OF TECHNOLOGICAL INTERVENTIONS IN PATIENTS WITH TYPE 2 DIABETES BY PRIMARY CARE PHYSICIANS AND ENDOCRINOLOGISTS IN THE UNITED STATES

Submitted

and 2 other(s)

9 Views
0 Downloads
0 Saves

Presentation

thumbnail

Abstract

Background and Aims: Determining when technological interventions (eg, insulin delivery devices [IDDs], continuous glucose monitoring (CGM) systems, smart phone applications) are appropriate to optimize treatment in patients with type 2 diabetes (T2D) can be challenging. This study assessed T2D diabetes technology (DT) practice trends among primary care physicians (PCPs) and endocrinologists (ENDOs) in the United States. Method: An online survey to assess the perspectives and use of DT (eg, IDD) was conducted in a sample of PCPs and ENDOs nationwide. To participate in this survey, at a minimum, PCPs treated ≥20 T2D patients/month, ≥25% receiving insulin; ENDOs treated ≥80 T2D patients/month, ≥50% receiving insulin. Respondent demographic results were analyzed by descriptive statistics. Results: Participants included 102 PCPs and 100 ENDOs. Fifty percent of ENDOs and 48% of PCPs report prescribing a traditional or wearable tube-free patch insulin pump when patients failed to achieve HbA1c targets with basal therapy plus ≥3 prandial injections of insulin/day. Participants ranked requiring fewer injections, glucose data versus insulin dosing graphical representation, and objectively capturing insulin dosing data as the most useful technologies of IDDs. Most important perceived features of an IDD were ease of use, flexible dosing, and large insulin reservoirs. Patients’ blood glucose control motivation, health literacy and/or cognitive ability, and previous good adherence were considered the strongest predictors for success with DT. Conclusions: PCPs and ENDOs who are highly focused on diabetes management report using IDDs when patients taking a basal injection plus ≥3 prandial injections of insulin are not achieving their HbA1c target.

Datasets

No datasets are available for this submission.

License

No license information is available for this submission.

Morressier

Company

Legal

Follow us

© Copyright 2020 Morressier GmbH. All rights reserved.

Morressier

© Copyright 2020 Morressier GmbH.
All rights reserved.